Evaluation of mediators of seasonal variation in fatal strokes: a multicentre registry-based cohort study.

J Stroke Cerebrovasc Dis

Department of Endocrinology, Ashford and St Peter's Hospitals NHS Foundation Trust, Guildford Road, Chertsey, Surrey KT16 0PZ, UK; Institute of Cardiovascular Research, Royal Holloway University of London, Egham, TW20 0EX, UK. Electronic address:

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objectives: How seasonal variations influence the incidence of fatal stroke remains unclear. Here, we examined potential mediators of the association between seasons and fatal strokes.

Methods: Data were prospectively collected (2014-2016) from the Sentinel Stroke National Audit Programme for admissions to four UK hyperacute stroke units. Relationships between variables were assessed by multivariable logistic regression, adjusted for age, sex and intracranial haemorrhage, and presented as odds ratios (OR) with 95 % confidence intervals (CI). The criteria for conducting a mediation analysis were met if the mediator was a continuous variable and was significantly associated both with the predictor and outcome variables.

Results: A total of 3,309 patients (50 % men, mean age=76.7 yr, SD=13.4) were admitted in spring (n = 830), summer (n = 733), autumn (n = 865) and winter (n = 881). There were no seasonal differences in age, sex distribution, co-morbidities (except congestive heart failure in summer) or stroke management. Compared to patients admitted in autumn, those admitted in winter had a greater risk of severe stroke: OR=2.22 (1.50-3.30), fatal stroke: OR=1.48 (1.13-1.93), palliative care: OR=1.85 (1.21-2.81) and pneumonia: OR=1.36 (1.00-1.85). Stroke severity was associated with a greater risk of fatal stroke: adjusted OR=1.14 (1.12-1.15). Mediation analysis revealed that the relationship between winter and fatal stroke was indeed mediated by stroke severity: indirect effect size=0.040 (0.012-0.068).

Conclusions: Our findings support evidence of increased incidence of fatal stroke in winter, which could be explained by greater stroke severity at this time. Further research is necessary to elucidate the underlying reason for greater severity of stroke in winter.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2025.108360DOI Listing

Publication Analysis

Top Keywords

fatal stroke
20
stroke
13
stroke severity
12
incidence fatal
8
age sex
8
mediation analysis
8
greater risk
8
stroke winter
8
fatal
7
winter
5

Similar Publications

The long-term prognostic value of the framingham risk scoring in patients with myocardial infarction with nonobstructive coronary arteries.

Am J Prev Cardiol

September 2025

Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Science and Peking Union Medical College, No. 167, North Lishi Road, Xicheng District, Beijing 100037, China.

Background: The Framingham Risk Score for Cardiovascular Disease (FRSCVD), based on the Framingham Heart Study, serves as a foundation for many prediction models. However, its applicability in predicting the long-term prognosis of patients experiencing myocardial infarction with nonobstructive coronary arteries (MINOCA) remains uncertain.

Methods: A cohort of 1158 MINOCA patients was enrolled and stratified into three groups based on 10-year FRSCVD risk.

View Article and Find Full Text PDF

It has become evident from decades of clinical trials that multimodal therapeutic approaches with focus on cell intrinsic and microenvironmental cues are needed to improve understanding and treat the rare, inoperable, and ultimately fatal diffuse intrinsic pontine glioma (DIPG), now categorized as a diffuse midline glioma. In this study we report the development and characterization of an in vitro system utilizing 3D Tumor Tissue Analogs (TTA), designed to replicate the intricate DIPG microenvironment. The innate ability of fluorescently labeled human brain endothelial cells, microglia, and patient-derived DIPG cell lines to self-assemble has been exploited to generate multicellular 3D TTAs that mimic tissue-like microstructures, enabling an in- depth exploration of the spatio-temporal dynamics between neoplastic and stromal cells.

View Article and Find Full Text PDF

Comparison of Short- and Long-Term Cardiovascular Disease Risk Assessment Tools in US Young Adults.

J Am Heart Assoc

September 2025

Department of Research & Evaluation Kaiser Permanente Southern California Pasadena CA USA.

Background: In 2023, the American Heart Association published the Predicting Risk of Cardiovascular Disease Events (PREVENT) equations for estimating atherosclerotic cardiovascular disease (ASCVD) risk in adults aged 30 to 79 years. We compared PREVENT's performance with existing US guideline recommended models-Pooled Cohort Equations for 10-year ASCVD risk and FHS (Framingham Heart Study) equations for 30-year ASCVD risk-among young adults.

Methods: We analyzed adults aged 20 to 39 years without baseline ASCVD from 2 sources: (1) pooled data from 2 large epidemiologic cohorts (CARDIA [Coronary Artery Risk Development in Young Adults] and FHS, n=7763), and (2) electronic health records from Kaiser Permanente Southern California (n=266 378).

View Article and Find Full Text PDF

Purpose: While SGLT-2i and GLP-1RA show cardiorenal benefits, their comparative efficacy in elderly type 2 diabetes mellitus (T2DM) patients remains uncertain. This study aimed to compare SGLT-2i and GLP-1RA on cardiovascular and renal outcomes in elderly T2DM patients.

Methods: This retrospective study analyzed 1,015 propensity score-matched elderly T2DM patients (SGLT-2i group: n = 583; GLP-1RA group: n = 432).

View Article and Find Full Text PDF

US eligibility and preventable cardiovascular disease events from semaglutide in type 2 diabetes.

Diab Vasc Dis Res

September 2025

Mary and Steve Wen Cardiovascular Division, School of Medicine, University of California, Irvine, CA, USA.

BackgroundThe SUSTAIN-6 trial showed the cardiovascular disease (CVD) benefits of semaglutide among patients with type 2 diabetes mellitus (T2DM). We estimated the US population eligibility and preventable CVD events from semaglutide.MethodsUS adults with T2DM were selected from the National Health and Nutrition Examination Survey 2011-2020 based on SUSTAIN-6 eligibility criteria.

View Article and Find Full Text PDF